CLSD Stock Overview
A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Clearside Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.87 |
| 52 Week High | US$2.12 |
| 52 Week Low | US$0.80 |
| Beta | 2.2 |
| 1 Month Change | -19.23% |
| 3 Month Change | -23.82% |
| 1 Year Change | -16.13% |
| 3 Year Change | -68.85% |
| 5 Year Change | -72.04% |
| Change since IPO | -87.97% |
Recent News & Updates
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16Shareholder Returns
| CLSD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -13.6% | -0.3% | -2.7% |
| 1Y | -16.1% | 7.9% | 23.4% |
Return vs Industry: CLSD underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: CLSD underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| CLSD volatility | |
|---|---|
| CLSD Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CLSD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CLSD's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 30 | George Lasezkay | clearsidebio.com |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Clearside Biomedical, Inc. Fundamentals Summary
| CLSD fundamental statistics | |
|---|---|
| Market cap | US$66.16m |
| Earnings (TTM) | -US$31.88m |
| Revenue (TTM) | US$7.70m |
8.6x
P/S Ratio-2.1x
P/E RatioIs CLSD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLSD income statement (TTM) | |
|---|---|
| Revenue | US$7.70m |
| Cost of Revenue | US$0 |
| Gross Profit | US$7.70m |
| Other Expenses | US$39.58m |
| Earnings | -US$31.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 100.00% |
| Net Profit Margin | -413.84% |
| Debt/Equity Ratio | -141.4% |
How did CLSD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 07:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clearside Biomedical, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Yi Chen | H.C. Wainwright & Co. |
| Esther Lannie Hong | Janney Montgomery Scott LLC |